Evidence map›Paper›PMID 37333358›Full record

ArticlebioRxiv : the preprint server for biology2023

Enhanced

Thomas J Esparza, Shiran Su, Caroline M Francescutti, Elvira Rodionova, Joong Hee Kim, David L Brody

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Thomas J EsparzaNational Institute of Neurological Disorders and Stroke, Bethesda, MD, United States of America.
Shiran SuNational Institute of Neurological Disorders and Stroke, Bethesda, MD, United States of America.
Caroline M FrancescuttiNational Institute of Neurological Disorders and Stroke, Bethesda, MD, United States of America.
Elvira RodionovaNational Institute of Neurological Disorders and Stroke, Bethesda, MD, United States of America.
Joong Hee KimNational Institute of Neurological Disorders and Stroke, Bethesda, MD, United States of America.
David L BrodyNational Institute of Neurological Disorders and Stroke, Bethesda, MD, United States of America.
Henry M. Jackson Foundation · USNational Institute of Neurological Disorders and Stroke · USUniformed Services University of the Health Sciences · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The blood brain barrier limits entry of macromolecular diagnostic and therapeutic cargos. Blood brain barrier transcytosis via receptor mediated transport systems, such as the transferrin receptor, can be used to carry macromolecular cargos with variable efficiency. Transcytosis involves trafficking through acidified intracellular vesicles, but it is not known whether pH-dependent unbinding of transport shuttles can be used to improve blood brain barrier transport efficiency. Methods: A mouse transferrin receptor binding nanobody, NIH-mTfR-M1, was engineered to confer greater unbinding at pH 5.5 vs 7.4 by introducing multiple histidine mutations. The histidine mutant nanobodies were coupled to neurotensin for Results: The most effective histidine mutant, M1 Conclusion: The pH-sensitive mouse transferrin receptor binding nanobody M1

Identifiers

PMID37333358
PMCPMC10274906
OpenAlexW4367186669

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.